Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. (2nd September 2022)

• Record Type: Journal Article
• Authors: Rodriguez, Cristina P; Kang, Hyunseok; Geiger, Jessica L; Burtness, Barbara; Chung, Christine H; Pickering, Curtis R; Fakhry, Carole; Le, Quynh Thu; Yom, Sue S; Galloway, Thomas J; Golemis, Erica; Li, Alice; Shoop, Jeffrey; Wong, Stuart; Mehra, Ranee; Skinner, Heath; Saba, Nabil F; Flores, Elsa R; Myers, Jeffrey N; Ford, James M; Karchin, Rachel; Ferris, Robert L; Kunos, Charles; Lynn, Jean M; Malik, Shakun
• Is Part Of: Journal of the National Cancer Institute. Volume 114:Number 12(2022)
• Page Start: 1619
• Page End: 1627
• Publication Date: 2022-09-02
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djac163
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus–negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53 -mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53- mutant HNSCC that can be conducted within the National Clinical Trials Network.